Last reviewed · How we verify
NCT03219632
Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG
trial testing Fimasartan in Left Ventricular Hypertrophy in 72 participants. Completed in 30 May 2017.
30 April 2017
Quick facts
| Lead sponsor | Seoul National University Bundang Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 72 |
| Start date | 5 June 2012 |
| Primary completion | 30 April 2017 |
| Estimated completion | 30 May 2017 |
Drugs / interventions tested
- Fimasartan (FIMASARTAN) — full drug profile →
Conditions studied
- Left Ventricular Hypertrophy — all drugs for Left Ventricular Hypertrophy →
- Hypertension — all drugs for Hypertension →
Sponsor
Seoul National University Bundang Hospital
Who can join
Adults 20 to 80, any sex, with Left Ventricular Hypertrophy or Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Assess the efficacy of fimasartan on left ventricular hypertrophy in hypertensive patients
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03219632
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fimasartan
Trials testing the same drug.
- NCT05930028 — A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patient · Phase 3 · completed
- NCT05173025 — Effect of Fimasartan on Extended RAS and Vascular Functions in Patients With Type 2 Diabetes and Hypertension · Phase 4 · unknown
Other recruiting trials for Left Ventricular Hypertrophy
Currently open trials in the same condition.
- NCT07263204 — AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy · recruiting
- NCT05593055 — Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension · Phase 4 · recruiting
- NCT05388032 — Sodium Lowering Vascular Effects Trial · NA · recruiting
- NCT05942729 — Etiological DiagnOsis of caRdiac Diseases Based on echoCardiograpHIc Images and Clinical Data. · recruiting
- NCT03549559 — Imaging Histone Deacetylase in the Heart · NA · recruiting
Other Seoul National University Bundang Hospital trials
Trials by the same sponsor.
- NCT07459725 — Comparison of EEG-Timed vs. Repetitive Robot Therapy for Chronic Stroke · NA · not yet recruiting
- NCT07455279 — Surface Electromyographic Analysis of Normal Swallowing in Children: An Exploratory Study · not yet recruiting
- NCT07477574 — Muscle-Specific Multimodal AI for Sarcopenia Diagnosis · NA · not yet recruiting
- NCT07505290 — Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial f · NA · active not recruiting
- NCT07305662 — Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGU · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03219632 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Bundang Hospital
- Last refreshed: 17 July 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03219632.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing